Vivo Bio Tech Limited has filed its quarterly dematerialization compliance certificate with BSE Limited, demonstrating adherence to regulatory requirements for the first quarter of fiscal year 2027.

Regulatory Compliance Filing

The company submitted the mandatory certificate on April 07, 2026, covering the period from January 01, 2026 to March 31, 2026. This filing fulfills the requirements under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Registrar Confirmation

M/s. Aarthi Consultants Private Limited, serving as the company's Registrar and Transfer Agent, provided the compliance certificate dated April 03, 2026. The registrar confirmed completion of all required dematerialization processes within the regulatory timeframe of 15 days.

Compliance Actions Completed

Aarthi Consultants Private Limited confirmed the following actions were completed during the quarter:

• Securities comprised in dematerialized certificates remain listed on appropriate stock exchanges
• Mutilation and cancellation of physical certificates forwarded by participants
• Substitution of depository name as registered owner in company records
• All processes completed within the mandated 15-day period upon receipt of certificates

Corporate Governance

The filing demonstrates Vivo Bio Tech Limited's commitment to maintaining regulatory compliance and transparent corporate governance practices. The company's systematic approach to dematerialization processes ensures investor protection and market integrity.

The certificate was signed by Compliance Officer Jagan Mohan Gobburi on behalf of Aarthi Consultants Private Limited, which operates as a Category I Registrar and Share Transfer Agent under SEBI Registration Number INR000000379.

Vivo Bio Tech promoter group member Kompella Lopa Mudra has disclosed the substantial acquisition of 90,000 equity shares under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition was completed on January 06, 2026, through the conversion of warrants issued on preferential basis.

Transaction Details

The acquisition involved the allotment of 90,000 equity shares through warrant conversion, representing 0.40% of the company's total share capital and 0.38% of the diluted share capital. The transaction was executed through preferential allotment mechanism.

Shareholding Pattern Changes

Following the acquisition, Kompella Lopa Mudra's shareholding structure has been restructured while maintaining the same total percentage holding. The conversion resulted in an increase in direct equity shareholding and a corresponding decrease in warrant holdings.

Before Acquisition:

After Acquisition:

Company Capital Structure

The transaction resulted in changes to Vivo Bio Tech Limited's equity share capital structure. The company's paid-up capital increased following the warrant conversion.

Regulatory Compliance

The disclosure was made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically under Regulation 29(2). The filing was submitted to BSE Limited on January 08, 2026, where Vivo Bio Tech Limited shares are listed under scrip code 511509. The diluted share capital calculation assumes conversion of outstanding 14,37,892 warrants into equity shares in future tranches.